TACSTD2
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesTACSTD2, EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1, TROP2, tumor-associated calcium signal transducer 2, tumor associated calcium signal transducer 2
External IDsOMIM: 137290 MGI: 1861606 HomoloGene: 1763 GeneCards: TACSTD2
Orthologs
SpeciesHumanMouse
Entrez

4070

56753

Ensembl

ENSG00000184292

ENSMUSG00000051397

UniProt

P09758

Q8BGV3

RefSeq (mRNA)

NM_002353

NM_020047

RefSeq (protein)

NP_002344

NP_064431

Location (UCSC)Chr 1: 58.58 – 58.58 MbChr 6: 67.51 – 67.51 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Tumor-associated calcium signal transducer 2, also known as Trop-2 and as epithelial glycoprotein-1 antigen (EGP-1),[5] is a protein that in humans is encoded by the TACSTD2 gene.[6][7][8]

This intronless gene encodes a carcinoma-associated antigen defined by the monoclonal antibody GA733. This antigen is a member of a family including at least two type I membrane proteins. It transduces an intracellular calcium signal and acts as a cell surface receptor.

Mutations of this gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.[8]

Trop-2 expression was originally described in trophoblasts (placenta) and fetal tissues (e.g., lung). Later, its expression was also described in the normal stratified squamous epithelium of the skin, uterine cervix, esophagus, and tonsillar crypts.[9]

Trop-2 plays a role in tumor progression by actively interacting with several key molecular signaling pathways traditionally associated with cancer development and progression. Aberrant overexpression of Trop-2 has been described in several solid cancers, such as colorectal, renal, lung, and breast cancers. Trop-2 expression has also been described in some rare and aggressive malignancies, e.g., salivary duct, anaplastic thyroid, uterine/ovarian, and neuroendocrine prostate cancers.[9]

This antigen is the target of sacituzumab govitecan, an antibody-drug conjugate.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000184292 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000051397 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan (IMMU-132) for Triple-Negative Breast Cancer Therapy
  6. Linnenbach AJ, Seng BA, Wu S, Robbins S, Scollon M, Pyrc JJ, et al. (March 1993). "Retroposition in a family of carcinoma-associated antigen genes". Molecular and Cellular Biology. 13 (3): 1507–1515. doi:10.1128/MCB.13.3.1507. PMC 359462. PMID 8382772.
  7. Calabrese G, Crescenzi C, Morizio E, Palka G, Guerra E, Alberti S (Apr 2001). "Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization". Cytogenetics and Cell Genetics. 92 (1–2): 164–165. doi:10.1159/000056891. PMID 11306819. S2CID 9708614.
  8. 1 2 "Entrez Gene: TACSTD2 tumor-associated calcium signal transducer 2".
  9. 1 2 Vranic S, Gatalica Z (February 2022). "Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers". Bosnian Journal of Basic Medical Sciences. 22 (1): 14–21. doi:10.17305/bjbms.2021.6100. PMC 8860310. PMID 34181512.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.